Search for Clinical Trial Results

Sponsored By

Cystadenocarcinoma, Mucinous - 25 Studies Found

Status Study
Completed Study Name: Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis
Condition: Noninvasive Mucinous Cystadenocarcinoma of Ovary
Date: 2014-04-22
Interventions: Other: A sampling of blood A sampling of blood de 14 ml
Terminated Study Name: Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
Condition:
  • Mucinous Cystic Tumor With Moderate Dysplasia
  • Mucinous Cystadenoma of Pancreas
  • Date: 2012-02-01
    Interventions: Drug: Ethanol and Paclitaxel Injection Endoscopic ultrasound will be used to locate and assess the pancr
Active, not recruiting Study Name: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
Condition:
  • Borderline Ovarian Mucinous Tumor
  • Ovarian Mucinous Cystadenocarcinoma<
    Date: 2010-03-04
    Interventions:
    • Biological: Bevacizumab Given

Recruiting Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Condition:
  • Acinar Cell Carcinoma
  • Adrenal Cortex Carcinoma
  • Adrenal Gla
    Date: 2016-07-13
    Interventions:
    • Procedure: Biospecimen Collection

Terminated Study Name: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Condition:
  • Malignant Ovarian Mixed Epithelial Tumor
  • Ovarian Clear Cell Cystadenocarcinoma
  • Date: 2000-01-28
    Interventions:
    • Drug: Carboplatin Given IV
Recruiting Study Name: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Condition:
  • Ovarian Brenner Tumor
  • Ovarian Carcinosarcoma
  • Ovarian Clear
    Date: 2014-03-28
    Interventions:
    • Drug: Gemcitabine Hydrochloride

Completed Study Name: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Condition:
  • Malignant Ovarian Mixed Epithelial Tumor
  • Ovarian Brenner Tumor
  • Drug: TLR8 Agonist VTX-2337 Gi
Suspended Study Name: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
Condition:
  • Nausea and Vomiting
  • Ovarian Brenner Tumor
  • Ovarian Clear Ce
    Date: 2011-01-11
    Interventions:
    • Procedure: Adjuvant Therapy An
Terminated Study Name: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Condition:
  • Adenocarcinoma of the Pancreas
  • Adenocarcinoma of the Stomach
  • Drug: veliparib Given PO
Active, not recruiting Study Name: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Condition:
  • Malignant Ovarian Mixed Epithelial Tumor
  • Ovarian Brenner Tumor
  • Biological: Bevacizumab Given

Next >>>